Qbrelis shortage: What providers and prescribers need to know in 2026

Qbrelis Shortage: What Providers and Prescribers Need to Know in 2026

Qbrelis (Lisinopril oral solution, 1 mg/mL) continues to present availability challenges in 2026. As the only FDA-approved ready-to-use Lisinopril oral solution, supply disruptions disproportionately affect pediatric patients, patients with dysphagia, and those requiring precise liquid dosing. This guide provides clinical context and actionable strategies for managing patients during periods of limited Qbrelis availability.

Current Supply Landscape

Qbrelis is manufactured exclusively by Azurity Pharmaceuticals. The single-source nature of this product makes it particularly vulnerable to supply chain disruptions. Contributing factors include:

• Single-manufacturer dependency: No competing manufacturers produce an FDA-approved Lisinopril oral solution.
• Limited retail pharmacy stocking: Low per-store demand means most retail pharmacies do not maintain Qbrelis inventory.
• No AB-rated generic: The absence of a generic Lisinopril oral solution limits substitution options at the pharmacy level.
• Distribution complexity: As a specialty product, Qbrelis may not be available through all wholesale distributors.

Providers should monitor the FDA Drug Shortage Database and ASHP Drug Shortage Resource Center for current status updates.

Clinical Impact

The Qbrelis shortage most significantly affects:

• Pediatric patients (≥6 years) with hypertension who require weight-based liquid dosing
• Patients with dysphagia who cannot swallow tablets safely
• Post-MI patients requiring early ACE inhibitor initiation who are unable to take oral solids
• Heart failure patients on complex regimens requiring precise dose titration in liquid form

Gaps in ACE inhibitor therapy can result in uncontrolled hypertension, heart failure exacerbation, and increased cardiovascular risk. Proactive management is essential.

Therapeutic Alternatives

1. Extemporaneously Compounded Lisinopril Suspension

Per USP guidelines, Lisinopril tablets can be compounded into a 1 mg/mL oral suspension. The standard formulation uses Lisinopril tablets, Bicitra (sodium citrate/citric acid), and Ora-Sweet SF or Ora-Plus as vehicles.

• Beyond-use date: Typically 4 weeks under refrigeration
• Advantages: Same active ingredient, adjustable concentration, lower cost
• Limitations: Requires compounding capability, shorter stability, batch-to-batch variability

2. Epaned (Enalapril Maleate Oral Solution)

Epaned is an FDA-approved Enalapril oral solution (1 mg/mL). Dose conversion from Lisinopril to Enalapril should account for differences in potency and pharmacokinetics. A general starting point: Lisinopril 10 mg ≈ Enalapril 10 mg twice daily, though individual titration is necessary.

3. Lisinopril Tablets

For patients who can transition to solid oral dosage forms, generic Lisinopril tablets (2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg) are widely available and cost-effective. Consider occupational therapy swallowing assessment if dysphagia severity is uncertain.

4. Captopril (Compounded Solution)

Captopril can be compounded into an oral solution. Shorter half-life requires BID-TID dosing. May be appropriate when Lisinopril compounding is unavailable.

5. Losartan Oral Suspension (ARB Alternative)

For patients with ACE inhibitor intolerance (e.g., persistent cough, angioedema history), compounded Losartan oral suspension is an option. This represents a class switch from ACE inhibitor to ARB.

Formulary and Insurance Considerations

Providers should be aware of common payer barriers:

• Prior authorization: Most commercial and Medicaid plans require PA for Qbrelis, with step therapy through Lisinopril tablets as first-line.
• Exception requests: Document medical necessity (dysphagia, pediatric patient, inability to use tablets) to support PA approval.
• Cost: Cash price for Qbrelis ranges from $690-$800 per 150 mL bottle. Generic Lisinopril tablets cost $4-$15 per month.

For savings resources to share with patients, see how to save money on Qbrelis and the provider-focused savings guide at how to help patients save money on Qbrelis.

Locating Qbrelis Supply

MedFinder for Providers offers real-time pharmacy inventory search to help you direct patients to pharmacies with current Qbrelis stock. This tool reduces patient burden and decreases the likelihood of missed doses during shortage periods.

Additional strategies:

• Direct patients to specialty pharmacies with established Qbrelis supply chains
• Consider mail-order pharmacy options through the patient's insurance plan
• Contact Azurity Pharmaceuticals for distribution and availability information

For a step-by-step approach, see how to help your patients find Qbrelis in stock.

Patient Communication Recommendations

When counseling patients during Qbrelis shortage periods:

• Emphasize the importance of not discontinuing ACE inhibitor therapy abruptly
• Explain the alternative plan clearly, including any dose or frequency changes
• Provide written instructions for compounded medications, including storage requirements
• Set follow-up appointments to monitor blood pressure after any medication changes
• Direct patients to MedFinder for Providers and share the patient-facing Qbrelis shortage update

Summary

The Qbrelis shortage requires proactive clinical management. Identify affected patients in your panel, establish alternative therapy plans, and leverage tools like MedFinder for Providers to streamline pharmacy location. For related clinical guidance, review our articles on Qbrelis drug interactions and Qbrelis side effects.